<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863821</url>
  </required_header>
  <id_info>
    <org_study_id>PL-201808008-M</org_study_id>
    <nct_id>NCT03863821</nct_id>
  </id_info>
  <brief_title>The Application and Analysis of HHHFNC in Walking Test of Pulmonary Rehabilitation</brief_title>
  <official_title>Effects of Heated Humidified High-Flow Nasal Cannula During Six-Minute Walk Test in Patient With COPD Undergoing Pulmonary Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu Jen Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fu Jen Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the use heated humidified high-flow nasal cannula
      (HHHFNC) in pulmonary rehabilitation and analysis of cardiopulmonary parameters in adult
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives： The aim of this study is to investigate the use heated humidified high-flow nasal
      cannula (HHHFNC) in pulmonary rehabilitation and analysis of cardiopulmonary parameters in
      adult patients.

      Background： Recently, HHHFNC has been used in both adult and neonates with post-extubation
      respiratory support. Studies indicate that HHHFNC has similar efficacy compared to
      non-invasive positive pressure ventilation and superior than conventional oxygen therapy.
      Six-minute walking test (6-MWT) is a standardized laboratory tests to evaluate the endurance
      capacity in adult patients. It helps clinician to modify the treatment plan. Cirio, et at.
      has been shown HHHFNC may improve the exercise performance in severe chronic obstructive
      pulmonary disease (COPD) patients with ventilatory limitation.

      Study Design： This is a prospective clinical trial in a pulmonary rehabilitation out-patient
      department (2018.08.01-2019.07.31).。 Methods： Patents with COPD who done pulmonary function
      test will enroll to this study. Left-side heart failure, COPD acute-exacerbation (AE) within
      3 months, diagnosed neuromuscular disease, and unable to perform 6-MWT will be exclude. The
      data will be collected for and analyzed.

      Effect： Investigators expect the exercise performance; cardiopulmonary function will be
      improve under HHHFNC support. We hope the application of HHHFNC in adult patient with
      pulmonary rehabilitation could enhance the quality of life.

      Key words： chronic obstructive pulmonary disease; heated humidified high-flow nasal cannula;
      pulmonary rehabilitation, six-minute walking test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants with COPD who done pulmonary function test will enroll to this study. Left-side heart failure, COPD AE within 3 months, diagnosed neuromuscular disease, and unable to perform 6-MWT will be exclude.
Participants will received HHHNFC or non-HHHFNC support during the 6-MWT.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Walking distance</measure>
    <time_frame>6 minutes</time_frame>
    <description>Meter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>1 hour</time_frame>
    <description>beat per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation (SpO2)</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous carbon dioxide (PtcCO2)</measure>
    <time_frame>1 hour</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output by non-invasive cardiometry</measure>
    <time_frame>1 hour</time_frame>
    <description>mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg dyspnea scale</measure>
    <time_frame>1 hour</time_frame>
    <description>0-10 level (level 10 means worst)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>COPD</condition>
  <condition>Pulmonary Disease</condition>
  <condition>Rehabilitation</condition>
  <arm_group>
    <arm_group_label>HHHFNC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Practice 6 MWT with HHHFNC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-HHHFNC group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Practice 6 MWT without HHHFNC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HHHFNC</intervention_name>
    <description>HHHFNC setting:
Flow rate: 40L/min
FiO2: 0.4
HHHFNC will use immediately before 6MWT and remove at the end of 6MWT</description>
    <arm_group_label>HHHFNC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD with performed pulmonary function test

        Exclusion Criteria:

          -  Left-side heart failure

          -  COPD exacerbation within 3 month

          -  Diagnosed neuromuscular disease

          -  Unable to perform 6-MWT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fu Jen Catholic University Hospital, Fu Jen Catholic University</name>
      <address>
        <city>New Taipei City</city>
        <zip>24352</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Cirio S, Piran M, Vitacca M, Piaggi G, Ceriana P, Prazzoli M, Paneroni M, Carlucci A. Effects of heated and humidified high flow gases during high-intensity constant-load exercise on severe COPD patients with ventilatory limitation. Respir Med. 2016 Sep;118:128-132. doi: 10.1016/j.rmed.2016.08.004. Epub 2016 Aug 8.</citation>
    <PMID>27578482</PMID>
  </results_reference>
  <results_reference>
    <citation>Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley JH. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014 Dec;8(6):169-81. doi: 10.1177/1753465814559209. Erratum in: Ther Adv Respir Dis. 2016 Jun;10(3):289.</citation>
    <PMID>25452426</PMID>
  </results_reference>
  <results_reference>
    <citation>Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, Donaldson N, Polkey MI, Moxham J. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004 Jun;59(6):471-6.</citation>
    <PMID>15170026</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fu Jen Catholic University</investigator_affiliation>
    <investigator_full_name>Ke-Yun, Chao</investigator_full_name>
    <investigator_title>Group leader of Respiratory Therapists</investigator_title>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>heated humidified high-flow nasal cannula</keyword>
  <keyword>pulmonary rehabilitation</keyword>
  <keyword>six-minute walking test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

